Identification of long non-coding RNAs that stimulate cell survival in bladder cancer

Dudek, Aleksandra; Boer, Sabrina; Boon, Nanda; Witjes, J.A.; Kiemeney, Lambertus A.; Verhaegh, Gerald W.

doi:10.18632/oncotarget.16284

Cited by 8 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, lncRNAs have been observed to serve as tumor suppressors or oncogenes because their dysregulation can promote or suppress the proliferation, migration, and invasion of BC cells [25][26][27]. In this study, because of the upregulation of LINC00707 in BC, we wondered that LINC00707 may act as a tumor promoter in BC.…”

Section: Discussionmentioning

confidence: 92%

Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop

Gao¹,

Ji²

2021

Urol Int

View full text Add to dashboard Cite

Introduction: Growing studies reveal that long noncoding RNA is involved in oncogenesis and progression. Previous studies have demonstrated that long intergenic noncoding RNA 00707 (LINC00707) stimulated tumor progress in numerous neoplasm types; however, the function of LINC00707 in bladder cancer (BC) was not yet clear. Our researches aimed to determine whether LINC00707 was dysregulated in BC and further study its biological functions. Methods: LINC00707 levels in BC tissues and cells were measured using reverse transcription-PCR (RT-PCR), and the associations between the levels of LINC00707 and clinicopathological features and the months of survival were also examined. Then, Cell Counting Kit-8 assays, flow cytometry, colony formation assays, and Transwell assays were applied for the assessment of the impact of LINC00707 on the abilities of BC cells. The interaction between LINC00707 and miR-145 or cell division cycle associated 3 was determined by luciferase reporter system and RT-PCR. Protein expressions of Wnt/β-catenin signaling were examined using RT-PCR and Western blot. Results: We found that LINC00707 expressions were notably upregulated in BC samples and cells. Higher expressions of LINC00707 were associated with T stage, grade, and shorter overall survival in BC patients. LINC00707 was also an independent prognostic factor for BC. In vitro assays confirmed that silencing LINC00707 expressions suppressed cell proliferation, colony formation, and metastasis. Mechanistic studies elucidated that LINC00707 was directly targeted to miR-145/CDCA3. Western blot assays revealed that Wnt/β-catenin signaling was inactivated by LINC00707 knockdown. Conclusion: Our work offers new insight into the function of LINC00707 in the tumorigenesis of BC.

show abstract

Section: Discussionmentioning

confidence: 92%

Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop

Gao¹,

Ji²

2021

Urol Int

View full text Add to dashboard Cite

show abstract

“…No additional studies were identified by a manual search of the references of the original studies. Finally, the remaining 37 articles were eligible for the systematic review (Wang et al, 2006 ; He et al, 2013 , 2016a , b ; Fan et al, 2014 ; Li et al, 2014 , 2017 ; Srivastava et al, 2014 ; Yan et al, 2014 ; Chen et al, 2015 , 2017 ; Eissa et al, 2015a , b ; Milowich et al, 2015 ; Zhao F. J. et al, 2015 ; Zhao X. L. et al, 2015 ; Duan et al, 2016 ; Iliev et al, 2016 ; Zhan et al, 2016a , b , 2017a , b ; Zhang et al, 2016 , 2017 ; Cao et al, 2017 ; Cui et al, 2017 ; Dudek et al, 2017 ; Du et al, 2017 ; Hu Y. Y. et al, 2017 ; Liao et al, 2017 ; Lin et al, 2017 ; Tolkach et al, 2017 ; Wu et al, 2017 ; Xiong et al, 2017 ; Yang et al, 2017 ; Ye et al, 2017 ; Zhuang et al, 2017 ), including 26 studies for clinicopathological parameters, 19 studies for prognosis, and 7 studies for diagnosis.…”

Section: Resultsmentioning

confidence: 99%

“…Conversely, an observed HR > 1 implied that the patients with increased lncRNAs expression had a worse survival. Increased expressions of MALAT1 (Fan et al, 2014 ; Li et al, 2017 ), ASAP1-IT1 (Yang et al, 2017 ), SPRY4-IT1 (Zhao X. L. et al, 2015 ), TUG1 (Iliev et al, 2016 ), lncRNA-n336928 (Chen et al, 2015 ), GHET1 (Li et al, 2014 ), linc-UBC1 (He et al, 2013 ), YRNA5 (Tolkach et al, 2017 ), XIST (Hu Y. Y. et al, 2017 ), PVT1 (Cui et al, 2017 ), and SNHG16 (Cao et al, 2017 ) were significantly correlated with poor prognosis in OS, along with decreased expressions of CAT1297 (Dudek et al, 2017 ), lncRNA-LET, YRNA1 (Tolkach et al, 2017 ), YRNA3 (Tolkach et al, 2017 ), YRNA4 (Tolkach et al, 2017 ), and NBAT1 (Du et al, 2017 ). It was worth noting that the most significant association was observed between increased expressions of SPRY4-IT1 and poor OS (HR = 3.716; 95% CI: 2.084–6.719; p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

Wang

2018

Front. Physiol.

View full text Add to dashboard Cite

Background: Increasing evidence shows that dysregulated expression of long non-coding RNAs (lncRNAs) can serve as diagnostic or prognostic markers in bladder cancer. The aim of this study was to evaluate the clinical values of dysregulated lncRNAs in bladder cancer.Methods: Eligible studies were systematically searched in PubMed, Embase, and Web of Science databases from inception to December 2017. Odds ratios (OR) were calculated to investigate the correlation between lncRNAs and clinicopathological parameters. Pooled hazard ratios (HR) and 95% confidence interval (CI) were calculated to explore the prognostic value of lncRNAs in bladder cancer. Pooled diagnostic parameters were also calculated to estimate the performance of lncRNAs in diagnosing bladder cancer. All statistical analyses were performed by using STATA 13.1 program.Results: A total of 37 relevant studies were included to the present systematic review according to the inclusion and exclusion criteria, including 26 on clinicopathological parameters, 19 on prognosis, and 7 on diagnosis. For clinicopathological parameters, MALAT1 expression was significantly associated with lymph node metastasis (OR = 2.731; 95% CI: 1.409–5.292; p = 0.003), and high-level expression of XIST was related to larger tumor size (OR = 2.473; 95% CI: 1.159–5.276; p = 0.019) and higher TNM stage (OR = 0.400; 95% CI, 0.184–0.868; p = 0.020). For the prognostic values, the most significant association was observed between increased expressions of SPRY4-IT1 and poor overall survival (OS) (HR = 3.716; 95% CI: 2.084–6.719; p < 0.001); high MALAT1 expression was significantly associated with poor OS (HR = 1.611; 95% CI: 1.076–2.412; p = 0.020). For the diagnostic values, UCA1 expression profile achieved a combined AUC of 0.92, with sensitivity of 0.84 and specificity of 0.89 in distinguishing patients with bladder cancer from non-cancerous controls.Conclusions: In summary, systematic review elaborated that abnormal lncRNAs expression can serve as potential markers for prognostic evaluation in bladder cancer patients. In addition, the diagnostic meta-analysis concluded that abnormally expressed UCA1 can function as potential diagnostic markers for bladder cancer.

show abstract

“…In previous researches, many different lncRNAs had been identified in bladder cancer, such as FOXD2-AS1, CAT266, CAT1297, CAT1647, LINC00857 and BANCR. [18][19][20][21] One of the main ways for lncRNAs to participate in tumor development is to act as an endogenous competitive RNA of microRNAs (miRNAs) and indirectly regulates gene expression post-transcriptionally. 5 LINC00963 has been found to be an oncogene in several human malignant tumors, including breast cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, etc.…”

Section: Discussionmentioning

confidence: 99%

LINC00963 Functions as an Oncogene in Bladder Cancer by Regulating the miR-766-3p/MTA1 Axis

Zhou¹,

Zhu²,

Man³

2020

CMAR

View full text Add to dashboard Cite

Long non-coding RNAs have been found to be involved in bladder cancer development. This article studied LINC00963 effects on bladder cancer progression to provide a novel treatment target. Patients and Methods: Totally 56 bladder cancer patients participated in this research. Bladder cancer cells were transfected. Cell counting kit 8 assay and clone formation experiment were used for cell viability and colony formation detection. Cell migration and invasion were determined by Transwell experiment. LINC00963 distribution was explored by cytoplasmic and nuclear extract isolation and quantitative real-time polymerase chain reaction. Luciferase reporter experiment and RNA pulldown experiment were performed to detect the relationship between these two genes. The cancer genome atlas analysis was used for the detection of metastasis-associated protein 1 (MTA1) expression in bladder cancer. Results: LINC00963 was seriously up-regulated in bladder cancer patients. High LINC00963 expression indicated high histological grade and low survival. LINC00963 was obviously up-regulated in bladder cancer cells. Knockdown of LINC00963 significantly reduced bladder cancer cells viability, colony formation, migration and invasion. Luciferase reporter experiment and RNA pulldown experiment revealed that LINC00963 promoted MTA1 expression via directly inhibiting miR-766-3p. MTA1 was up-regulated in bladder cancer patients. MTA1 up-regulation reversed the inhibitory effect of LINC00963 knockdown on bladder cancer cell viability, migration and invasion. Conclusion: LINC00963 functions as an oncogene in bladder cancer by regulating the miR-766-3p/MTA1 axis.

show abstract

Identification of long non-coding RNAs that stimulate cell survival in bladder cancer

Cited by 8 publications

References 37 publications

Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop

Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop

Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review

<p>LINC00963 Functions as an Oncogene in Bladder Cancer by Regulating the miR-766-3p/MTA1 Axis</p>

Contact Info

Product

Resources

About